Search Results - "Layos, L."

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) by Carrato, A, Benavides, M, Massutí, B, Ferreiro-Monteagudo, R, García Alfonso, P, Falcó, E, Reboredo, M, Cano, T, Gallego, J, Viéitez, J M, Layos, L, Salud, A, Polo, E, Dotor, E, Durán-Ogalla, G, Rodriguez-Garrote, M, Calvo, A, Grande, E, Aranda, E

“…Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of…”
Get full text

Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry? by Font, R., Espinas, J.A., Layos, L., Martinez Villacampa, M., Capdevila, J., Tobeña, M., Pisa, A., Pericay, C., Lezcano, C., Fort, E., Cardona, I., Berga, N., Solà, J., Borras, J.M.

“…Preoperative oral capecitabine plus radiotherapy has been progressively adopted in oncology units to provide more convenient care to patients with rectal…”
Get full text

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy by Martinez-Balibrea, E, Abad, A, Martínez-Cardús, A, Ginés, A, Valladares, M, Navarro, M, Aranda, E, Marcuello, E, Benavides, M, Massutí, B, Carrato, A, Layos, L, Manzano, J L, Moreno, V

“…Background: The impact of thymidylate synthase (TYMS) and UDP-glucoronosyltransferase 1A (UGT1A) germline polymorphisms on the outcome of colorectal cancer…”
Get full text

Expression patterns and prognostic value of Cyclin-dependent kinase 5 (Cdk5) in colorectal tumours by de Porras, V. Ruiz, Cabrero-De las Heras, S, Bystrup, S, Subirats, J.L, Musulén, E, Manzano, J.L, Moreno, V, Layos, L, Bugés, C, Martinez-Balibrea, E

Get full text

2059 Adherence to oral therapy in rectal cancer patients in Catalonia, Spain by Font, R, Espinas, J.A, Sola, J, Layos, L, Tobena, M, Capdevila, J, Martinez, M, Alfaro, J, Bonfill, T, Albanell, J, Paez, D, Dotor, E, Manchon-Walsh, P, Andres, J. Borras

Get full text

6003 ORAL Role of KRas Status in Patients With Metastatic Colorectal Cancer Receiving First-line Chemotherapy Plus Bevacizumab – a TTD Spanish Group Cooperative Study by Garcia, E. Diaz-Rubio, Gomez, A, Yuste, A, Puente, J, Lopez-Lopez, C, Safont, M.J, Layos, L, Reboredo, M, Benavides, M, Aranda, E

Get full text

Clinical impact of 18F-FDG-PET/CT (PET) in patients (P) with oligometastatic disease (OMD) at a skin and gastrointestinal tumour section by Garcia-Mosquera, J J, Layos Romero, L, Buges, C, España Fernandez, S, Chen, S, Velarde, J M, Felip, E, Erasun Lecuona, C, Angelats, L, Cucurull Salamero, M, Manzano, J L

Get full text

4004 Cetuximab plus capecitabine as first-line treatment for elderly patients (pts) with advanced colorectal cancer (mCRC). Final analysis of activity and survival according to KRAS status – the TTD-06–01 Spanish Cooperative Group trial by Rivera, F, Gravalos, C, Massutí, B, Puente, J, Marcuello, E, Valladares, M, Gutiérrez, V, Layos, L, Díaz-Rubio, E, Aranda, E

Get full text

6121 Gene expression profile related to oxaliplatin (OXA) intrinsic resistance in a panel of 14 human colorectal cancer (CRC) cell lines by Martinez-Cardus, A, Martinez-Balibrea, E, Bandrés, E, Malumbres, R, Manzano, J.L, Ginés, A, Layos, L, Quiroga, V, Garcia-Foncillas, J, Abad, A

Get full text

P54 Study of ATP7B copper transporter mRNA levels as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin by Martinez-Cardus, A, Martinez-Balibrea, E, Gines, A, Manzano, J.L, Aranda, E, Musulén, E, Layos, L, Abad, A

Get full text

P-313 Management of frail patients with metastatic pancreatic ductal adenocarcinoma: A single-institution experience by Salarich, A. Plaja, Díez, A. Ferrando, Badia, A. Pous, Rincon, L. Notario, Fernández, S. España, Martín, F. Pérez, Carbó, C. Hierro, Sánchez, C. Bugés, Mozo, J. Manzano, Romero, L. Layos

Get full text

P-318 Survival outcomes among patients with locally advanced gastric cancer treated within a multidisciplinary gastro-esophageal cancer functional unit by Díez, A. Ferrando, Salarich, A. Plaja, Carbó, C. Hierro, Savall, E. Garsot, Gallarín, M. Caro, Font, A. Clavell, Romero, L. Layos, Fernández, S. España, Calduch, O. García, Iniesta, R. Rodríguez, Hernández, J. Colan, Martos, R. López, Berna, A. Calsina, Madroño, M. Sendrós, Gonzalez, M. Sendra, Olivares, M. Riquelme, Marfil, A. Hernandez, Cuellar, M. López, Osuna, M. José, Pous, A. Font, Mozo, J. Manzano, Sánchez, C. Bugés

Get full text

P-317 Survival outcomes among patients with locally advanced esophageal cancer treated within a multidisciplinary gastro-esophageal cancer functional unit by Salarich, A. Plaja, Díez, A. Ferrando, Sánchez, C. Bugés, Carbó, C. Hierro, Gallarín, M. Caro, Martín, M. Viciano, Fernández, S. España, Calduch, O. García, Torres, E. Barluenga, Hernández, J. Colan, Martos, R. López, Gonzalez, M. Sendra, Pardo, M. Álvaro, Ortiz, C. Joaquin, Olivares, M. Riquelme, Marfil, A. Hernandez, Ruiz, N. Calderon, Cuellar, M. López, Osuna, M. José, Romero, L. Layos, Mozo, J. Manzano, Pous, A. Font

Get full text

Phase II randomized trial of capecitabine + radiation therapy with/without bevacizumab as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: Final results of 3 and 5-year disease free survival, distant relapse free survival and overall survival by Gravalos, C., Capdevila, J., Layos, L., Pericay, C., Martínez-Villacampa, M., López López, C., Losa, F., Safont, M.J., Gómez-España, A., Alonso, V., Escudero, P., Gallego, J., García-Paredes, B., Palacios, A., Biondo, S., Salazar, R., Aranda Aguilar, E.

Get full text

882 - Expression patterns and prognostic value of Cyclin-dependent kinase 5 (Cdk5) in colorectal tumours by de Porras, V. Ruiz, Cabrero-De las Heras, S., Bystrup, S., Subirats, J.L., Musulén, E., Manzano, J.L., Moreno, V., Layos, L., Bugés, C., Martinez-Balibrea, E.

Get full text

Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry? by Font, R, Espinàs Piñol, Josep Alfons, Layos, L, Martínez Villacampa, Mercedes, Capdevila, Jaume, Tobeña, M, Pisa, Aleydis, Pericay, Carles, Lezcano, C, Fort, E, Cardona, I, Berga, N, Solà, Judit, Borràs Andrés, Josep Maria

“…Background: Preoperative oral capecitabine plus radiotherapy has been progressively adopted in oncology units to provide more convenient care to patients with…”
Get full text

551PRAS ANALYSIS OF THE PLANET STUDY: PHASE II TRIAL OF PANITUMUMAB (P) PLUS FOLFOX4 OR FOLFIRI IN SUBJECTS WITH WILD-TYPE (WT) KRAS COLORECTAL CANCER (CRC) AND LIVER-LIMITED DISEASE (LLD) by Abad, A., Sureda, B. Massuti, Grávalos, C., Escudero, P., Guillen-Ponce, C., Gómez, A., Safont, M.J., Plazas, J. Gallego, Sastre, J., Pericay, C., Dueñas, R., López, C., Losa, F., Valladares-Ayerbes, M., Flores, E. González, Díaz, L. Robles, Layos, L., Carrato, A., Aranda, E.

“…Abstract Aim: Patients (pts) with RAS mutations other than KRAS exon 2 do not benefit from P. We explored the effect of these mutations in the efficacy of…”
Get full text

Ras Analysis of the Planet Study: Phase Ii Trial of Panitumumab (P) Plus Folfox4 or Folfiri in Subjects with Wild-Type (Wt) Kras Colorectal Cancer (Crc) and Liver-Limited Disease (Lld) by Abad, A., Sureda, B. Massuti, Grávalos, C., Escudero, P., Guillen-Ponce, C., Gómez, A., Safont, M.J., Plazas, J. Gallego, Sastre, J., Pericay, C., Dueñas, R., López, C., Losa, F., Valladares-Ayerbes, M., Flores, E. González, Díaz, L. Robles, Layos, L., Carrato, A., Aranda, E.

Get full text

Panitumumab Plus FOLFOX4 or Panitumumab Plus Folfiri in Subjects with Wild-Type KRAS (EXON 2) Colorectal Cancer and Multiple or Unresectable Liver-Limited Metastases: Data from the Randomized, Phase II Planet Study by Abad, A., Massutí, B., Grávalos, C., Escudero, P., Guillén-Ponce, C., Layos, L., Gomez, M.A., Safont, M.J., Gallego, J., Sastre, J., Pericay, C., Dueñas, R., López-López, C., Losa, F., Valladares, M., González-Flores, E., Yuste, A., Robles, L., Sáenz, A., Cano, T., Carrato, A., Aranda, E.

Get full text

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy by Martinez Balibrea, E, Abad, Albert, Martínez Cardús, Anna, Ginés, A, Valladares, M, Navarro, M, Aranda, E, Marcuello, Eugenio, Benavides, M, Massutí, B, Carrato, A, Layos, L, Manzano, J. L, Moreno Aguado, Víctor

“…BACKGROUND: The impact of thymidylate synthase (TYMS) and UDP-glucoronosyltransferase 1A (UGT1A) germline polymorphisms on the outcome of colorectal cancer…”
Get full text